Prelude Therapeutics

formerly Prelude Therapeutics IncorporatedIPO

Delivering Precision Medicines to Patients with Cancer

Public · Wilmington, United States · Founded 2016 · $145.0M raised

Employees
51–200
Founded
2016
Business Model
B2B
Total Funding
$145.0M
Last Round
$50.0M Series CAug 2020
Rounds
4
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 7 funding rounds and 3 investors for this company. The full record is or through the API.

About

Prelude Therapeutics is a clinical-stage precision oncology company developing medicines for genomically defined cancers with high unmet need. Its pipeline includes highly selective KAT6A degraders and mutant-selective JAK2V617F JH2 inhibitors, plus next-generation degrader antibody conjugates that apply its targeted protein degradation expertise. The company aims to extend precision medicine to every cancer patient in need.

Summary

Prelude Therapeutics is a Biotech company based in Wilmington, United States, founded in 2016. It has raised $145.0M in total across 4 rounds, most recently a $50.0M Series C round in Aug 2020. Investors include OrbiMed, RA Capital Management and Fidelity Management.

Tech & App Stack

4 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Secondary MarketSecondary MarketApr 2026

Sign up to see all 7 events

Funding: Series A through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
Avenzo

Avenzo is a San Diego, CA-based biopharma company to in-license and develop the next generation o...

San Diego, United States1–10Biotech, Oncology
Series BTotal funding$832.0MSep 2025
Bicycle TherapeuticsIPO

Novel bicyclic peptides and drug conjugates for cancer

Cambridge, United States201–500Biotech, Oncology
Private EquityTotal funding$607.0MJan 2024
Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Prelude Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/prelude-therapeutics"><img src="https://indexed.vc/api/badge/company/prelude-therapeutics" alt="Prelude Therapeutics on Indexed.vc" width="260" height="76" /></a>